肝细胞癌
癌基因
癌症研究
分子医学
细胞凋亡
激活剂(遗传学)
细胞周期
上皮-间质转换
索拉非尼
细胞生长
生物
癌症
医学
内科学
受体
转移
生物化学
遗传学
作者
Jiansong Wu,Qiang Niu,Jie Yuan,Xiaodan Xu,Liuxia Cao
出处
期刊:Experimental and Therapeutic Medicine
[Spandidos Publications]
日期:2019-10-07
被引量:2
标识
DOI:10.3892/etm.2019.8080
摘要
Although it is known that Phenazine biosynthesis-like domain-containing protein (PBLD) expression is downregulated in hepatocellular carcinoma (HCC), its biological function is unclear. Additionally, no agents capable of upregulating PBLD exist. In the current study, the relationship between PBLD and HCC was analyzed using clinicopathological specimens. A HCC cell model, microarray analysis and an animal model were used to verify the therapeutic effect of cedrelone on HCC. The present study demonstrated that PBLD inhibited HCC progression. Furthermore, the present study revealed that cedrelone possessed treated-HCC capabilities via targeted PBLD overexpression. The epithelial-mesenchymal transition phenotype and growth rate were inhibited and the apoptosis ratio was promoted by cedrelone following PBLD overexpression. The Ras and Ras-proximate-1 signaling pathways were also determined to be regulated by cedrelone via PBLD activation in HCC. PBLD may therefore be an independent predictor of HCC progression and a novel target for HCC treatment. Additionally, the PBLD activator, cedrelone, may be a potential drug for HCC treatment in the future.
科研通智能强力驱动
Strongly Powered by AbleSci AI